Inclusion Criteria

DISEASE CHARACTERISTICS:

- Pathologically confirmed neuroendocrine tumor metastatic to the liver

- Well-differentiated or moderately well-differentiated neuroendocrine tumors

- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm with
conventional techniques or ≥ 10 mm with spiral CT scan

- Symptomatic disease, meeting one of the following criteria:

- Refractory carcinoid symptoms, defined as Carcinoid Symptom Severity scale > 2
despite use of octreotide acetate at ≥ 200 mcg subcutaneously three times daily
(or 20 mg intramuscularly once monthly) for ≥ 4 weeks

- Evidence of radiographic progression with either of the following
manifestations:

- Moderate-severe right upper quadrant pain and unintentional weight loss >
10%

- Decline in Karnofsky performance status > 10 points

- At least a 20% increase in the sum of the longest diameters of target lesions in the
liver within the past 12 months

- No more than 75% replacement of normal liver by neuroendocrine tumor

- No more than 20% arteriovenous lung shunting on a technetium Tc 99m macro-aggregated
albumin nuclear scan

- No equivocal, nonmeasurable, or nonevaluable liver metastasis

PATIENT CHARACTERISTICS:

- Karnofsky performance status 50-100%

- Life expectancy ≥ 6 months

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Creatinine ≤ 1.5 mg/dL

- Bilirubin ≤ 2.0 mg/dL

- Albumin ≥ 3.0 g/dL

- Absolute granulocyte count ≥ 1,500/mm³

- Platelet count ≥ 65,000/mm³

- Hemoglobin > 9.0 g/dL

- INR ≤ 1.4

- No hepatic arterial anatomy that would preclude the administration of study treatment
into the liver

- No nonmalignant disease that would preclude study participation

- No other malignancy within the past 5 years except for cured basal cell carcinoma of
the skin or cured carcinoma in situ of the uterine cervix

PRIOR CONCURRENT THERAPY:

- Prior surgery, chemotherapy, or locally ablative technique for the liver cancer
allowed

- No prior radiotherapy to the upper abdomen that includes the liver in the treatment
field

- No investigational drug or agent/procedure (i.e., participation in another clinical
trial) within the past 4 weeks

- No other specific anticancer treatment (other than octreotide acetate) during and for
3 months after completion of study therapy